What is CTKB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.71B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CTKB?

P/E (TTM) is n/a and 52-week range is $3.31 to $6.21 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CTKB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CTKB?

The company profile lists revenue (TTM) near $206M, net income (TTM) near $-8.04B, EPS (TTM) near $-0.63 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cytek Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Fremont, California, US, 129.1M shares outstanding, ISIN US23285D1090 when available from company profile and filing metadata.

Cytek Biosciences Inc

$CTKB

Health Care · Life Sciences Tools & Services

IR Run Scenarios

$5.43

+1.31%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 702 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Employees

702

Website

cytekbio.com

IPO

2021-07-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)